Key result
Balloon aortic valvuloplasty carries a ~17% MACCE rate, predicted by intubation and higher peak gradient.
Why the study?
Balloon aortic valvuloplasty remains a vital tool, but characterization of patients and predictors of procedural success, major adverse cardiovascular and cerebrovascular events, and in-hospital mortality needed investigation.
Observational (n=136)
No
Balloon aortic valvuloplasty remains a viable bridge to definitive treatment or palliative option, though associated with significant periprocedural risks.
May aid periprocedural risk stratification in BAV; hypothesis-generating pending prospective validation.
BACKGROUND: Balloon aortic valvuloplasty (BAV) remains a vital tool as a bridge to definitive treatment, a palliative therapy, or a stabilizing procedure for hemodynamically unstable patients. AIMS: Our aim was to characterize patients undergoing BAV and identify predictors of procedural success, major adverse cardiovascular and cerebrovascular events, and in-hospital mortality. METHODS: This retrospective, single-center registry embraced consecutive patients undergoing BAV between 2010 and 2022. Procedural success was defined as mean pressure gradient reduction > 10 mm Hg. Major adverse cardiovascular and cerebrovascular events was the primary composite endpoint. RESULTS: Among 136 patients (57 men [41.9%]; mean [standard deviation] age 78.5 [8.9] years), BAV was performed as: a bridge to transcatheter aortic valve implantation (n = 42, 30.9%), palliative procedure (n = 49, 36.0%), prognostic procedure during transcatheter aortic valve implantation qualification (n = 33, 24.3%). Sixteen patients underwent percutaneous coronary intervention (14 before [10.3%] and 2 during BAV [1.5%]). Procedural success was reported in 60 patients (44.1%) and independently associated with a higher mean pressure gradient (odds ratio [OR], 1.09; 95% confidence interval: 1.002-1.19; P = 0.04). Major adverse cardiovascular and cerebrovascular events occurred in 23 patients (16.9%), was independently predicted by a higher maximal aortic valve gradient (OR, 1.02; P = 0.014) and need for intubation (OR, 15.5; P = 0.003). In-hospital mortality was 6.6%, with precedent percutaneous coronary intervention being its independent predictor (OR, 32.0; P = 0.015). Patients after successful BAV more frequently underwent subsequent aortic valve replacement. CONCLUSIONS: Balloon aortic valvuloplasty remains a valuable procedure, particularly as a bridge to definitive treatment. Major adverse cardiovascular and cerebrovascular events and mortality risk remains significant, highlighting the fragile nature of the patients' population.
No takes yet. Share an insight, caveat, or question.
Kampka et al. (2026) conducted an observational in Aortic stenosis (n=136). Balloon aortic valvuloplasty was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE). In patients undergoing balloon aortic valvuloplasty, major adverse cardiovascular and cerebrovascular events occurred in 16.9% of cases, with higher maximal aortic valve gradient and need for intubation as independent predictors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: